BioSpace News Archive

Enabled by a national network of trusted, long-standing relationships with medical professionals, Quest HealthConnect provides a personalized approach, often at members’ homes, through an on-site Health Risk Assessment.

The medical advisory board of the Pulmonary Fibrosis Foundation (PFF), the nation’s leading pulmonary fibrosis (PF) research, education, and advocacy organization, has issued a position statement on non-prescription supplemental oxygen.

Because millions of people experience fatal venous and arterial thrombosis – blood clots – per year and those with COVID-19 are at higher risk, researchers at The Feinstein Institutes for Medical Research helped to design and implement an entirely virtual, outpatient, cloud-based clinical trial to understand the efficacy of a common prophylactic medication: rivaroxaban.

Akoya Biosciences, Inc., The Spatial Biology Company®, announced its financial results for the first quarter ending March 31, 2023.

Shockwave Medical, Inc. (Nasdaq: SWAV), a pioneer in the development and commercialization of Intravascular Lithotripsy (IVL) to treat complex calcified cardiovascular disease, today reported financial results for the three months ended March 31, 2023.

Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced financial results for the first quarter ended March 31, 2023 and provided a business update.

Adamis Pharmaceuticals announced that it will host an investor conference call on Monday, May 15, 2023 at 2:00 pm PT to discuss its financial and operating results for the first quarter 2023 as well as provide a corporate update, which may include an update concerning the results of the company’s special meeting of stockholders scheduled to be held on May 15, 2023 at 10:00 am PT as well as the proposals to be considered and acted upon at the meeting.

Solid Biosciences Inc. announced that Bo Cumbo, President and Chief Executive Officer, will present at the JMP Securities Life Sciences Conference on Monday, May 15, 2023 at 1:00 PM ET.

Annexon, Inc. reported first quarter 2023 financial results and highlighted recent progress across its portfolio of complement therapies.

Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today reported financial results for the first quarter ended March 31, 2023, and provided updates on its ophthalmology pipeline.